Search results
Results from the WOW.Com Content Network
Choroideremia (/ k ɒ ˌ r ɔɪ d ɪ ˈ r iː m i ə /; CHM) is a rare, X-linked recessive form of hereditary retinal degeneration that affects roughly 1 in 50,000 males. The disease causes a gradual loss of vision, starting with childhood night blindness, followed by peripheral vision loss and progressing to loss of central vision later in life.
Osteitis fibrosa cystica (/ ˌ ɒ s t i ˈ aɪ t ɪ s f aɪ ˈ b r oʊ s ə ˈ s ɪ s t ɪ k ə / OSS-tee-EYE-tis fy-BROH-sə SIS-tik-ə) is a skeletal disorder resulting in a loss of bone mass, a weakening of the bones as their calcified supporting structures are replaced with fibrous tissue (peritrabecular fibrosis), and the formation of cyst-like brown tumors in and around the bone.
Metabolic bone disease is an abnormality of bones caused by a broad spectrum of disorders. Most commonly these disorders are caused by deficiencies of minerals such as calcium, phosphorus, magnesium or vitamin D leading to dramatic clinical disorders that are commonly reversible once the underlying defect has been treated.
Osteopenia, known as "low bone mass" or "low bone density", is a condition in which bone mineral density is low. [1] Because their bones are weaker, people with osteopenia may have a higher risk of fractures, and some people may go on to develop osteoporosis. [2]
Senile osteoporosis has been recently recognized as a geriatric syndrome with a particular pathophysiology. There are different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. [1]
All forms of renal osteodystrophy should also be distinguished from other bone diseases which may equally result in decreased bone density (related or unrelated to CKD): osteoporosis [19] osteopenia [20] osteomalacia [21] brown tumor should be considered as the top-line diagnosis if a mass-forming lesion is present. [22] [23]
Despite the clinic’s failure rate, she has not considered making the medication more accessible. “I don’t know how to answer that question,” she said. “We are an abstinence-based program by nature.” The state’s treatment providers have little idea how their patients fare once they walk out the door.
Granulocyte-colony stimulating factor (G-CSF) is one possible treatment for neutropenia. [12] Monitoring weight gain and growth is crucial, as well as annual ophthalmologic and hematologic evaluations and checkups. [8] While there are treatments available to people with Cohen syndrome, there are no known cures for the disease. [citation needed]